EP2742154A4 - Biomarkerzusammensetzungen und verfahren damit - Google Patents
Biomarkerzusammensetzungen und verfahren damitInfo
- Publication number
- EP2742154A4 EP2742154A4 EP12821745.2A EP12821745A EP2742154A4 EP 2742154 A4 EP2742154 A4 EP 2742154A4 EP 12821745 A EP12821745 A EP 12821745A EP 2742154 A4 EP2742154 A4 EP 2742154A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- biomarker compositions
- biomarker
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161521333P | 2011-08-08 | 2011-08-08 | |
US201161523763P | 2011-08-15 | 2011-08-15 | |
US201161526623P | 2011-08-23 | 2011-08-23 | |
US201161529762P | 2011-08-31 | 2011-08-31 | |
US201161534352P | 2011-09-13 | 2011-09-13 | |
US201161537462P | 2011-09-21 | 2011-09-21 | |
US201161542639P | 2011-10-03 | 2011-10-03 | |
US201161551674P | 2011-10-26 | 2011-10-26 | |
US201161559676P | 2011-11-14 | 2011-11-14 | |
US201261612111P | 2012-03-16 | 2012-03-16 | |
US201261619803P | 2012-04-03 | 2012-04-03 | |
PCT/US2012/050030 WO2013022995A2 (en) | 2011-08-08 | 2012-08-08 | Biomarker compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2742154A2 EP2742154A2 (de) | 2014-06-18 |
EP2742154A4 true EP2742154A4 (de) | 2015-08-12 |
Family
ID=47669214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12821745.2A Withdrawn EP2742154A4 (de) | 2011-08-08 | 2012-08-08 | Biomarkerzusammensetzungen und verfahren damit |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2742154A4 (de) |
JP (1) | JP2014522993A (de) |
KR (1) | KR20140067001A (de) |
CN (1) | CN103874770A (de) |
AU (1) | AU2012294458A1 (de) |
BR (1) | BR112014002975A2 (de) |
CA (1) | CA2844671A1 (de) |
WO (1) | WO2013022995A2 (de) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102089444A (zh) | 2008-05-14 | 2011-06-08 | 德玛泰克国际公司 | 利用核酸分析方法来诊断黑素瘤和太阳能雀斑 |
WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
EP2556172A4 (de) | 2010-04-06 | 2013-10-30 | Caris Life Sciences Luxembourg Holdings | Zirkulierende biomarker für krankheiten |
JP6352909B2 (ja) | 2012-06-27 | 2018-07-04 | バーグ エルエルシー | 前立腺癌の診断および処置におけるマーカーの使用 |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
CN103160509B (zh) * | 2013-03-07 | 2015-02-18 | 新乡医学院第一附属医院 | 一种与食管癌术后早期复发和预后相关的miRNA标志物及其应用 |
CA2905081C (en) * | 2013-03-15 | 2023-10-03 | Beth Israel Deaconess Medical Center, Inc. | Mirna biogenesis in exosomes for diagnosis and therapy |
CN104076151B (zh) * | 2013-03-29 | 2017-04-12 | 复旦大学附属华山医院 | 一种用于胶质瘤早期诊断的试剂盒 |
AU2014261505B2 (en) * | 2013-04-29 | 2019-04-18 | Apogenix Ag | Method of diagnosing cancer |
WO2014183093A1 (en) | 2013-05-10 | 2014-11-13 | University Of Southern California | Dna methylation biomarkers for bladder cancer |
WO2015021158A1 (en) * | 2013-08-06 | 2015-02-12 | Exosome Diagnostics, Inc. | Urine biomarker cohorts, gene expression signatures, and methods of use thereof |
AU2014312211A1 (en) * | 2013-08-28 | 2016-03-10 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
PT3039424T (pt) * | 2013-08-28 | 2020-09-03 | Crown Bioscience Inc Taicang | Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo |
US10139402B2 (en) | 2013-11-06 | 2018-11-27 | Jsr Corporation | Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy of disease treatment drug, kit, and liquid composition |
FR3014198B1 (fr) * | 2013-12-03 | 2017-03-03 | Biomerieux Sa | Procede d'isolement d'exosomes |
EP3078889B1 (de) * | 2013-12-06 | 2019-09-18 | The University of Tokyo | Ventil, fluidsteuerungsstruktur, fluidvorrichtung und verfahren zur herstellung eines ventils |
CA2934828A1 (en) * | 2013-12-30 | 2015-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medici, Inc. | Prostate cancer gene profiles and methods of using the same |
JP2017503169A (ja) | 2013-12-31 | 2017-01-26 | イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド | オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断 |
WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
EP3137909B1 (de) | 2014-04-29 | 2018-06-06 | Apogenix AG | Diagnostischer anti-cd95l-antikörper |
CN107075568A (zh) * | 2014-05-01 | 2017-08-18 | 阿姆斯特丹自由大学医学中心基金会 | 作为生物标记物的小ncRNA |
ES2481819B1 (es) * | 2014-06-12 | 2015-04-01 | Sistemas Genómicos, S.L. | Método de evaluación para evaluar una posibilidad de cáncer de mama |
KR102557689B1 (ko) | 2014-06-12 | 2023-07-20 | 국립연구개발법인 고쿠리츠간켄큐센터 | 전립선암 검출 키트 또는 디바이스 및 검출 방법 |
US20160038608A1 (en) * | 2014-08-07 | 2016-02-11 | National Taiwan University | Silica-based mesoporous carrier and delivery method of using the same |
EP3198023B1 (de) * | 2014-09-26 | 2020-04-22 | Somalogic, Inc. | Vorhersage eines kardiovaskulären risikoereignisses und verwendungen davon |
KR101596166B1 (ko) | 2014-10-07 | 2016-02-19 | 가톨릭대학교 산학협력단 | 유방암 진단 및 치료를 위한 마이크로 rna의 용도 |
CN104313171A (zh) * | 2014-11-06 | 2015-01-28 | 南京大学 | 一种诊断神经胶质瘤的microRNA分子标记物及其应用 |
US10539566B2 (en) | 2014-12-08 | 2020-01-21 | Berg Llc | Use of markers including filamin A in the diagnosis and treatment of prostate cancer |
CN105807063B (zh) * | 2014-12-29 | 2018-02-06 | 中国人民解放军第二军医大学 | Cd63在制备肝脏疾病诊断试剂盒或制备预防或治疗肝脏疾病药物中的应用 |
CN104548134A (zh) * | 2015-01-04 | 2015-04-29 | 中国人民解放军第二军医大学 | miR-144及其抑制剂的应用 |
WO2016112031A1 (en) * | 2015-01-05 | 2016-07-14 | The Johns Hopkins University | Method of epigenetic analysis for determining clinical genetic risk |
WO2016121821A1 (ja) * | 2015-01-27 | 2016-08-04 | Jsr株式会社 | 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液 |
EP3865139B1 (de) | 2015-02-18 | 2023-05-03 | Enlivex Therapeutics Rdo Ltd | Kombinationsimmuntherapie und cytokinkontrolltherapie zur krebsbehandlung |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
WO2016139659A1 (en) | 2015-03-01 | 2016-09-09 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
WO2016145128A1 (en) | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
CN104714032B (zh) * | 2015-04-02 | 2015-09-16 | 闫星宇 | 用于产后子痫诊断的标志物及其检测试剂 |
AU2016250570B2 (en) | 2015-04-21 | 2021-07-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
CN108271413A (zh) * | 2015-05-20 | 2018-07-10 | Jsr株式会社 | 分离方法、检测方法、信号测定方法、疾病的判定方法、药效评价方法、试剂盒、液态组合物以及检体稀释液 |
BR112017026467A2 (pt) | 2015-06-10 | 2018-09-11 | Univ Texas | uso de exossomos para o tratamento de doença |
CN104992058B (zh) * | 2015-06-25 | 2017-08-01 | 成都厚立信息技术有限公司 | 疾病风险调整模型建立方法 |
CA2991045A1 (en) | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides binding c1q |
CN105177117A (zh) * | 2015-07-03 | 2015-12-23 | 张理义 | 重症抑郁障碍生物标记物、筛选方法及试剂盒 |
CN106350578A (zh) * | 2015-07-13 | 2017-01-25 | 中国人民解放军第二军医大学 | Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用 |
WO2017019918A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
CN105039342B (zh) * | 2015-08-06 | 2017-12-01 | 李家平 | 能抑制MAT2A基因表达的siRNA及其应用 |
US20180231565A1 (en) * | 2015-08-09 | 2018-08-16 | Immunarray Ltd | Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes |
CN105067822B (zh) * | 2015-08-12 | 2017-05-24 | 中山大学附属肿瘤医院 | 用于食管癌诊断的标志物 |
JP6583817B2 (ja) * | 2015-09-04 | 2019-10-02 | 国立大学法人山口大学 | 子宮平滑筋における腫瘍の診断マーカー |
JP6857185B2 (ja) * | 2015-09-11 | 2021-04-14 | アプタマー サイエンス インコーポレイテッドAptamer Sciences Inc. | 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法 |
BR112018005175A2 (pt) | 2015-09-17 | 2018-10-16 | Amgen Inc | predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23 |
EP3165926A1 (de) * | 2015-11-06 | 2017-05-10 | Humanitas Mirasole S.p.A. | Verfahren zur charakterisierung von zellspezifischen mikrovesikeln |
WO2017112921A1 (en) * | 2015-12-24 | 2017-06-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for characterizing sepsis |
WO2017113565A1 (zh) * | 2015-12-29 | 2017-07-06 | 中国医学科学院肿瘤医院 | 基于蛋白标志物psg3辅助诊断肝癌或消化道癌症患者的试剂盒 |
AU2017219415B2 (en) | 2016-02-18 | 2023-08-10 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
KR20190008843A (ko) | 2016-03-18 | 2019-01-25 | 카리스 싸이언스, 인코포레이티드 | 올리고뉴클레오티드 프로브 및 이의 용도 |
CN105842461A (zh) * | 2016-04-30 | 2016-08-10 | 广州恒泰生物科技有限公司 | 子宫肉瘤早中期快速诊断试剂盒及其制备方法 |
US11293017B2 (en) | 2016-05-25 | 2022-04-05 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
CN107475356A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 骨肉瘤循环肿瘤细胞鉴定试剂盒 |
CN105907875A (zh) * | 2016-06-13 | 2016-08-31 | 武汉泰安康生物科技有限公司 | 一种筛选肾癌外周血miRNA标志物的方法及肾癌标志物miR-378 |
JP6980219B2 (ja) * | 2016-08-22 | 2021-12-15 | いであ株式会社 | がんを検出、又はがんの進行期を判定する方法 |
WO2018091419A1 (en) * | 2016-11-15 | 2018-05-24 | Ventana Medical Systems, Inc. | Compositions and methods for prognosing and treating colorectal cancer |
CN108165635B (zh) * | 2016-12-07 | 2021-07-13 | 南京农业大学 | Kiaa1462基因启动子区变异位点及其在提高鹅产蛋性能上的应用 |
GB2561940A (en) * | 2016-12-16 | 2018-10-31 | Brigham & Womens Hospital Inc | System and method for protein corona sensor array for early detection of diseases |
US20210072255A1 (en) | 2016-12-16 | 2021-03-11 | The Brigham And Women's Hospital, Inc. | System and method for protein corona sensor array for early detection of diseases |
CN106636296A (zh) * | 2016-12-22 | 2017-05-10 | 广州医科大学附属肿瘤医院 | Hsp27在舌癌化疗耐受诊治中的应用 |
CN106501517B (zh) * | 2016-12-27 | 2018-05-08 | 北京蛋白质组研究中心 | 检测血清中sparc蛋白的物质在制备筛查肝细胞癌试剂盒中的应用 |
CN106939340A (zh) * | 2017-03-31 | 2017-07-11 | 哈尔滨医科大学 | 一种与肺腺癌转移及预后相关的分子标记物及其应用 |
CN106947820B (zh) * | 2017-04-11 | 2020-09-29 | 成都望路医药技术有限公司 | Vcan在结肠腺癌诊治中的用途 |
WO2018209161A1 (en) * | 2017-05-12 | 2018-11-15 | The Regents Of The University Of Michigan | Individual and cohort pharmacological phenotype prediction platform |
CN106987649A (zh) * | 2017-05-31 | 2017-07-28 | 上海博慷生物科技有限公司 | 一种用于检测脑胶质瘤的引物组及检测方法 |
CN109085355A (zh) * | 2017-06-13 | 2018-12-25 | 中国医学科学院肿瘤医院 | 血清蛋白标志物组合在肺癌筛查和诊治中的应用 |
CN107273718A (zh) * | 2017-06-27 | 2017-10-20 | 电子科技大学 | 一种融合dna甲基化特征的生存时间分析方法 |
JP7029719B2 (ja) * | 2017-08-31 | 2022-03-04 | 静岡県 | バイオマーカー |
CN107630092B (zh) * | 2017-10-23 | 2020-03-31 | 广州医科大学附属第二医院 | miR-505-3p应用于前列腺癌骨转移的诊断、预后和治疗 |
CN111512158B (zh) * | 2017-12-22 | 2023-12-12 | 威斯康星校友研究基金会 | 用于癌症生物标志物捕获的纳米工程化表面 |
CN107868829B (zh) * | 2017-12-26 | 2021-05-18 | 浙江自贸区锐赛生物医药科技有限公司 | 评估脊索瘤术后复发风险的组合试剂、试剂盒及其应用 |
CN107937621A (zh) * | 2018-01-12 | 2018-04-20 | 南方医科大学皮肤病医院(广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心) | miRNA的应用、应用其的产品及检测方法 |
CN108192970A (zh) * | 2018-01-24 | 2018-06-22 | 苏州大学 | 一种肝癌诊断标志物及其应用 |
CN108048460B (zh) * | 2018-02-01 | 2021-04-09 | 浙江大学 | 一种新型分子标记及其在制备用于头颈癌诊断和预后的试剂盒中的应用 |
CA3095056A1 (en) | 2018-04-13 | 2019-10-17 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
FR3080185A1 (fr) * | 2018-04-16 | 2019-10-18 | Biomerieux | Evaluation du risque de complication chez un patient suspecte d'avoir une infection ayant un score sofa inferieur a deux |
CN108559778B (zh) * | 2018-04-28 | 2020-06-12 | 北京师范大学 | 多发性骨髓瘤分子分型及其在用药指导上的应用 |
CN108570501B (zh) * | 2018-04-28 | 2020-06-12 | 北京师范大学 | 多发性骨髓瘤分子分型及应用 |
CN108586579B (zh) * | 2018-05-11 | 2021-11-30 | 京东方科技集团股份有限公司 | 一种类肽及其衍生物、盐、制备方法和用途 |
CN113855675A (zh) * | 2018-05-22 | 2021-12-31 | 郑州大学第一附属医院 | 基于胆囊癌标志物的试剂盒及药物 |
CN108841962B (zh) * | 2018-08-01 | 2021-11-19 | 博奥生物集团有限公司 | 一种非小细胞肺癌检测试剂盒及其应用 |
KR102094608B1 (ko) * | 2018-08-08 | 2020-04-23 | 고려대학교 산학협력단 | 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법 |
JP7378739B2 (ja) | 2018-08-10 | 2023-11-14 | 東レ株式会社 | 前立腺がんの検出のためのキット、デバイス及び方法 |
CN109321656B (zh) * | 2018-10-22 | 2021-10-01 | 上海交通大学医学院附属仁济医院 | 蛋白depdc1作为诊断三阴乳腺癌的标记物的用途 |
JP2020074769A (ja) * | 2018-11-01 | 2020-05-21 | 花王株式会社 | 被験体の皮膚細胞に由来する核酸の調製方法 |
CN109507425A (zh) * | 2018-11-07 | 2019-03-22 | 国家纳米科学中心 | 基于热泳细胞外囊泡的前列腺癌症复发监控系统及方法 |
AU2019374692A1 (en) | 2018-11-07 | 2021-06-03 | Seer, Inc. | Compositions, methods and systems for protein corona analysis and uses thereof |
WO2020104588A1 (en) * | 2018-11-22 | 2020-05-28 | Institut D'investigació Sanitària Pere Virgili | Biomarkers of prostate cancer aggressiveness |
CN109609630B (zh) * | 2018-12-03 | 2023-01-13 | 哈尔滨医科大学 | 用于早期胃癌诊断的分子标志物及其应用 |
CN109439757A (zh) * | 2018-12-18 | 2019-03-08 | 首都医科大学附属北京佑安医院 | 血浆外泌体miR-455-3p作为早期肝癌诊断标志物的应用 |
CN109652504B (zh) * | 2018-12-27 | 2021-03-16 | 杭州迪相实业有限公司 | 一种同时检测外泌体膜蛋白和mRNA的方法 |
JP2022517563A (ja) * | 2019-01-02 | 2022-03-09 | チョーチアン クラウンマブ バイオテック カンパニー リミテッド | タンパク質キナーゼバイオマーカーと組み合わせた、多標的キナーゼ阻害剤を使用したがんの処置 |
CN109609653B (zh) * | 2019-02-12 | 2019-07-19 | 山东大学齐鲁医院 | 诊断或治疗胶质瘤的分子标记物及其应用 |
EP3699300A1 (de) * | 2019-02-22 | 2020-08-26 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Samen-mirnas als nicht-invasive biomarker zur diagnose und/oder prognose von prostatakrebs |
US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
CN110196329A (zh) * | 2019-05-31 | 2019-09-03 | 郑州大学第一附属医院 | 一种食管癌早期联合检测试剂盒 |
JPWO2020262374A1 (de) * | 2019-06-27 | 2020-12-30 | ||
CN110279707A (zh) * | 2019-07-05 | 2019-09-27 | 深圳市康宁医院(深圳市精神卫生研究所深圳市精神卫生中心) | miR-212在制备用于治疗成瘾的药物中的应用 |
US20220291233A1 (en) * | 2019-07-19 | 2022-09-15 | Universiteit Antwerpen | Mucin isoforms in diseases characterized by barrier dysfunction |
KR102346864B1 (ko) * | 2019-07-24 | 2022-01-04 | 한국전자기술연구원 | 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법 |
CN117129704A (zh) | 2019-08-05 | 2023-11-28 | 禧尔公司 | 用于样品制备、数据生成和蛋白质冠分析的系统和方法 |
CN110295228A (zh) * | 2019-08-05 | 2019-10-01 | 中国人民解放军总医院第八医学中心 | 检测gata2的物质在制备诊断活动性结核病的试剂盒中的应用 |
CN110551809A (zh) * | 2019-08-21 | 2019-12-10 | 昆明医科大学第一附属医院 | miR-124在脊髓损伤修复中的用途 |
CN110564867B (zh) * | 2019-10-10 | 2022-06-24 | 扬州大学 | 一种秦川牛cfl1基因的snp分子标记及其检测方法 |
CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
JPWO2021132654A1 (de) * | 2019-12-27 | 2021-07-01 | ||
CN111647658B (zh) * | 2020-06-05 | 2022-09-27 | 上海市第一人民医院 | Linc00963相关致癌轴在前列腺癌远处转移的早期诊断和治疗中的应用 |
CN111690746A (zh) * | 2020-06-30 | 2020-09-22 | 镇江维思生物科技有限责任公司 | 与肺癌相关的血小板rna标志物及其应用 |
CN113940999B (zh) * | 2020-07-15 | 2022-11-29 | 中国农业大学 | 一种治疗非酒精性脂肪肝性肝病治疗靶点的应用 |
CN112180100A (zh) * | 2020-09-27 | 2021-01-05 | 西安交通大学 | Tweak作为鉴别不同类型银屑病的分子标志物的应用 |
CN112255408B (zh) * | 2020-10-16 | 2023-04-14 | 牡丹江医学院 | 一种肿瘤生物标志物及肿瘤检测试剂盒 |
CN112285195B (zh) * | 2020-10-27 | 2021-08-10 | 江南大学 | 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法 |
CN112433053A (zh) * | 2020-11-20 | 2021-03-02 | 四川大学华西医院 | Tetraspanin-14蛋白检测试剂在制备肺癌筛查试剂盒中的用途 |
CN112301133B (zh) * | 2020-12-01 | 2021-07-27 | 江门市中心医院 | 胆固醇生成基因标签在年轻乳腺癌患者预后预测中的应用 |
KR102427057B1 (ko) * | 2020-12-04 | 2022-07-29 | 전남대학교산학협력단 | 단일섬유종양/혈관주위세포종 전이 진단 또는 예후 분석용 바이오 마커 및 이를 이용한 진단방법 |
US20240052422A1 (en) | 2020-12-24 | 2024-02-15 | Pontificia Universidad Catolica De Chile | In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method |
CN113151460B (zh) * | 2021-01-29 | 2022-10-18 | 复旦大学附属中山医院 | 一种识别肺腺癌肿瘤细胞的基因标志物及其应用 |
CN115166245A (zh) * | 2021-04-04 | 2022-10-11 | 兰州大学第一医院 | Clu及其组合物在诊断胆管癌中的应用及胆管癌诊断试剂盒 |
KR102540416B1 (ko) * | 2021-04-09 | 2023-06-12 | 주식회사 애티스랩 | 암 진단용 조성물, 키트, 및 이를 이용한 암 진단 방법 |
CN113125757B (zh) * | 2021-04-22 | 2022-10-28 | 石河子大学 | 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠检测的方法 |
CN113122544A (zh) * | 2021-04-25 | 2021-07-16 | 杭州广科安德生物科技有限公司 | 一种特异性结合timp1蛋白的核酸适配体及其应用 |
CN113311166B (zh) * | 2021-04-28 | 2022-10-28 | 新疆农垦科学院 | 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法 |
CN113186267A (zh) * | 2021-06-07 | 2021-07-30 | 上海康黎诊断技术有限公司 | 一种人cyp2d6拷贝数变异和基因分型检测的引物探针组合、试剂盒以及方法 |
CN113687076B (zh) * | 2021-07-14 | 2024-03-01 | 郑州大学 | 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用 |
GB202111635D0 (en) * | 2021-08-13 | 2021-09-29 | Randox Laboratories | Risk prediction model for prostate cancer |
WO2023054436A1 (ja) * | 2021-09-29 | 2023-04-06 | 株式会社西尾 | 美容方法 |
WO2023064883A1 (en) * | 2021-10-14 | 2023-04-20 | The University Of Chicago | Immunotherapeutic methods for treating cancer |
WO2023140658A1 (ko) * | 2022-01-24 | 2023-07-27 | 고려대학교 산학협력단 | 뇌유래신경성장인자를 이용한 패혈증 진단, 예방 또는 치료용 약학적 조성물 |
WO2023169686A1 (en) * | 2022-03-10 | 2023-09-14 | Buzzard Pharmaceuticals AB | Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer |
WO2024050856A1 (zh) * | 2022-09-06 | 2024-03-14 | 南京市第一医院 | 一种辅助血细胞分析仪判定异常血小板聚集的方法和系统 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008092153A2 (en) * | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
WO2009015357A1 (en) * | 2007-07-25 | 2009-01-29 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
EP1697497A4 (de) * | 2003-11-03 | 2008-04-23 | Gene News Inc | Leberkrebs-biomarker |
EP1904645B1 (de) * | 2005-07-08 | 2010-08-04 | Siemens Healthcare Diagnostics GmbH | Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
US20100248225A1 (en) * | 2006-11-06 | 2010-09-30 | Bankaitis-Davis Danute M | Gene expression profiling for identification, monitoring and treatment of melanoma |
EP2222345B1 (de) * | 2007-11-23 | 2016-03-23 | British Columbia Cancer Agency Branch | Verfahren zum nachweis von lungenkrebs und zur überwachung des ansprechens auf die behandlung |
US8617806B2 (en) * | 2008-01-25 | 2013-12-31 | Hansabiomed Ou | Method to measure and characterize microvesicles in the human body fluids |
US20110177054A1 (en) * | 2008-06-06 | 2011-07-21 | Derrick Gibbings | Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna |
WO2010062706A2 (en) * | 2008-10-30 | 2010-06-03 | Caris Mpi, Inc. | Methods for assessing rna patterns |
GB0822836D0 (en) * | 2008-12-15 | 2009-01-21 | Oxford Biomedica Ltd | Method |
EP2475989A4 (de) * | 2009-09-09 | 2013-02-27 | Gen Hospital Corp | Verwendung von mikrovesikeln bei der analyse von kras-mutationen |
US20110166030A1 (en) * | 2009-09-30 | 2011-07-07 | Yixin Wang | Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells |
CA2782284A1 (en) * | 2009-11-30 | 2011-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods and systems for isolating, storing, and analyzing vesicles |
-
2012
- 2012-08-08 BR BR112014002975A patent/BR112014002975A2/pt not_active IP Right Cessation
- 2012-08-08 KR KR1020147004204A patent/KR20140067001A/ko not_active Application Discontinuation
- 2012-08-08 CN CN201280049340.2A patent/CN103874770A/zh active Pending
- 2012-08-08 WO PCT/US2012/050030 patent/WO2013022995A2/en active Application Filing
- 2012-08-08 EP EP12821745.2A patent/EP2742154A4/de not_active Withdrawn
- 2012-08-08 AU AU2012294458A patent/AU2012294458A1/en not_active Abandoned
- 2012-08-08 JP JP2014525128A patent/JP2014522993A/ja active Pending
- 2012-08-08 CA CA2844671A patent/CA2844671A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008092153A2 (en) * | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
WO2009015357A1 (en) * | 2007-07-25 | 2009-01-29 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
Non-Patent Citations (3)
Title |
---|
T. DENG ET AL: "Abstract 444: Subpopulations of circulating microvesicles have different microRNA profiles", CANCER RESEARCH, vol. 71, no. 8 Supplement, 15 April 2011 (2011-04-15), pages 444 - 444, XP055168378, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2011-444 * |
TA DENG ET AL: "Subpopulations of Circulating Microvesicles Have Different MicroRNA Profiles", 7 April 2011 (2011-04-07), XP055168385, Retrieved from the Internet <URL:http://www.carislifesciences.com/media/pdf/Spetzler-sorted-MiRs-AACR-poster-2011.pdf> [retrieved on 20150209] * |
TRACI PAWLOWSKI ET AL: "Circulating exosomes may provide an alternate platform to monitor disease progression compared to circulating tumor cells CD-81 Labeled Exosome Level vs CTCs in Plasma Derived Exosomes miR-21 Copy Number vs CTCs in EpCAM+ Plasma Derived Exosomes", 5 July 2010 (2010-07-05), XP055168408, Retrieved from the Internet <URL:http://www.carislifesciences.com/media/pdf/ASCO_Pawlowski2010.pdf> [retrieved on 20150209] * |
Also Published As
Publication number | Publication date |
---|---|
CN103874770A (zh) | 2014-06-18 |
WO2013022995A2 (en) | 2013-02-14 |
CA2844671A1 (en) | 2013-02-14 |
KR20140067001A (ko) | 2014-06-03 |
EP2742154A2 (de) | 2014-06-18 |
AU2012294458A1 (en) | 2014-02-27 |
BR112014002975A2 (pt) | 2017-03-01 |
JP2014522993A (ja) | 2014-09-08 |
WO2013022995A3 (en) | 2013-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100012I1 (hu) | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók | |
EP2742154A4 (de) | Biomarkerzusammensetzungen und verfahren damit | |
EP2721179A4 (de) | Biomarkerzusammensetzungen und verfahren dafür | |
EP2922861A4 (de) | Biomarkerzusammensetzungen und verfahren | |
EP2823306A4 (de) | Biomarkerzusammensetzungen und verfahren | |
PL2791160T3 (pl) | Kompozycje zmodyfikowanego mrna | |
HK1202625A1 (en) | Compositions and methods for assessing appendicitis | |
ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
GB201408236D0 (en) | Composition and method | |
GB201122195D0 (en) | Composition and method | |
EP2672822A4 (de) | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen | |
GB201411762D0 (en) | Precoating methods and compositions | |
EP2734646A4 (de) | Zusammensetzungen und verfahren zur auswahl von atomaren | |
EP2667710A4 (de) | Insektizidzusammensetzungen und zugehörige verfahren | |
ZA201308892B (en) | Compositions and methods | |
EP2766357A4 (de) | Mesobiliverdinzusammensetzungen und verfahren dafür | |
IL227384A0 (en) | Metal steaming compounds and methods for chemical-mechanical polishing | |
GB201106433D0 (en) | Composition and method | |
IL239426A0 (en) | Methods and compositions of biomarkers | |
HK1203232A1 (en) | Biomarker and use thereof | |
IL231798A0 (en) | method and preparation | |
IL230868A0 (en) | Biomarker preparations and methods | |
GB201116340D0 (en) | Compositions and methods | |
GB201117620D0 (en) | Method and composition | |
GB201116421D0 (en) | Composition and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140226 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101ALI20150217BHEP Ipc: G01N 33/68 20060101ALI20150217BHEP Ipc: G01N 33/53 20060101ALI20150217BHEP Ipc: G01N 33/566 20060101ALI20150217BHEP Ipc: C12Q 1/68 20060101AFI20150217BHEP Ipc: G01N 33/574 20060101ALI20150217BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BROWN, KIRK Inventor name: SPETZLER, DAVID Inventor name: PAWLOWSKI, TRACI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PAWLOWSKI, TRACI Inventor name: BROWN, KIRK Inventor name: SPETZLER, DAVID |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150713 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101ALI20150707BHEP Ipc: G01N 33/53 20060101ALI20150707BHEP Ipc: G01N 33/574 20060101ALI20150707BHEP Ipc: G01N 33/566 20060101ALI20150707BHEP Ipc: C12Q 1/68 20060101AFI20150707BHEP Ipc: G01N 33/68 20060101ALI20150707BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170516 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170927 |